Issued Patents All Time
Showing 26–50 of 108 patents
| Patent # | Title | Co-Inventors | Date |
|---|---|---|---|
| 10221413 | Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2 | Joseph Collard | 2019-03-05 |
| 10174324 | Treatment of Methionine sulfoxide reductase a (MSRA) related diseases by inhibition of natural antisense transcript to MSRA | Joseph Collard | 2019-01-08 |
| 10113166 | Treatment of filaggrin (FLG) related diseases by modulation of FLG expression and activity | Joseph Collard, Carlos Coito | 2018-10-30 |
| 10100315 | Treatment of PAR4 related diseases by inhibition of natural antisense transcript to PAR4 | Joseph Collard | 2018-10-16 |
| 10053691 | Treatment of NANOG related diseases by inhibition of natural antisense transcript to NANOG | Joseph Collard | 2018-08-21 |
| 10036014 | Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene | Joseph Collard | 2018-07-31 |
| 10000752 | Antagonat compositions and methods of use | Joseph Collard, Belinda De Leon | 2018-06-19 |
| 9970008 | Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1 | Joseph Collard | 2018-05-15 |
| 9957503 | Treatment of LCAT gene related diseases by inhibition of a natural antisense transcript to LCAT | Joseph Collard | 2018-05-01 |
| 9920369 | Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisene transcript to CSF3 | Joseph Collard | 2018-03-20 |
| 9920322 | Treatment of vascular endothelial growth factor (VEGF) related diseases by inhibition of natural antisense transcript to VEGF | Joseph Collard | 2018-03-20 |
| 9914923 | Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor | Joseph Collard | 2018-03-13 |
| 9909126 | Treatment of Adiponectin (ADIPOQ) related diseases by inhibition of natural antisense transcript to an Adiponectin (ADIPOQ) | Joseph Collard | 2018-03-06 |
| 9902959 | Treatment of Frataxin (FXN) related diseases by inhibition of natural antisense transcript to FXN | Joseph Collard | 2018-02-27 |
| 9902995 | Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related disease by inhibition of natural antisense transcript to PYCR1 | Joseph Collard | 2018-02-27 |
| 9902958 | Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG | Joseph Collard, Carlos Coito | 2018-02-27 |
| 9879264 | Treatment of membrane bound transcription factor peptidase, site 1 (MBTPS1) related diseases by inhibition of natural antisense transcript to MBTPS1 | Joseph Collard | 2018-01-30 |
| 9879256 | Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF | Joseph Collard | 2018-01-30 |
| 9873873 | Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA | Joseph Collard, Carlos Coito, Gang Shen | 2018-01-23 |
| 9834769 | Treatment of delta-like 1 homolog (DLK1) related diseases by inhibition of natural antisense transcript to DLK1 | Joseph Collard, Carlos Coito | 2017-12-05 |
| 9834767 | Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8 | Joseph Collard | 2017-12-05 |
| 9809816 | Treatment of NANOG related diseases by inhibition of natural antisense transcript to NANOG | Joseph Collard | 2017-11-07 |
| 9771579 | Treatment of sodium channel, voltage-gated, alpha subunit (SCNA) related diseases by inhibition of natural antisense transcript to SCNA | Joseph Collard, Belinda De Leon, Carlos Coito, Jane Hsiao | 2017-09-26 |
| 9771593 | Treatment of tumor necrosis factor receptor 2 (TNFR2) related diseases by inhibition of natural antisense transcript to TNFR2 | Joseph Collard | 2017-09-26 |
| 9765336 | Treatment of erythropoietin (EPO) related diseases by inhibition of natural antisense transcript to EPO | Joseph Collard | 2017-09-19 |